Article Impact Level: HIGH Data Quality: STRONG Summary of Circulation: Heart Failure, 0(0). https://doi.org/10.1161/CIRCHEARTFAILURE.122.010080 Dr. Scott Solomon et al
Points
- The trial’s main goal was to evaluate the effectiveness and safety measures of Dapagliflozin in patients with heart failure by preserved ejection fraction.
- Efficacy and safety measures were determined by age groups and across ages.
- The results of this study indicated that cardiovascular death or heart failure were reduced due to dapagliflozin in different age groups, particularly those above ages of 75 years.
Summary
The pervasiveness of heart failure with preserved or mildly reduced ejection fraction was found to be related to increases in age, and extra risk for death and hospitalization was found excessively in older age. The effectiveness and safety measures of Dapagliflozin were found recently across a broad spectrum of ages with reduced ejection fraction in heart failure patients, but benefits were unknown with mildly reduced or preserved ejection fraction in heart failure patients.
Preserved Ejection Fraction Heart Failure trial was carried out to evaluate dapagliflozin in order to improve the survival of patients with heart failure by comparing the effectiveness and safety of dapagliflozin and placebo for mildly reduced or preserved ejection fraction across a wide-ranging age from 40 to 99 years. The clinical trials included 6263 patients, in 20 countries, out of which 338 were more than 55 years, 1,007 were between 55-64 years, 2326 were range from 65-74 years, and 2592 were more than 75 years which represents 5.4%, 16.1%, 37.1%, 41.4% respectively. Randomization method was used to place patients in dapagliflozin 10mg group or placebo dose once daily group after their consent for a screening period of 21 days.
Older patients showed a higher pervasiveness of atrial fibrillation and flutter, but heart rate, HbA1c, diastolic blood pressure, and BMI were lower with increasing age. All age groups showed a reduced risk of primary composite in comparison to placebo with dapagliflozin. It was also found that no significant interactions were between treatment and age groups, and increased age relates to adverse effects. Dapagliflozin and placebo showed no significant differences across all age groups in predefined safety outcomes. Dapagliflozin across the range of age in patients with heart failure reduced cardiovascular death or deteriorating heart failure events.
Link to the article: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.122.010080
References Peikert, A., Martinez, F. A., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Shah, S. J., Katova, T., Merkely, B., Vardeny, O., Wilderäng, U., Lindholm, D., … Solomon, S. D. (n.d.). Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: The deliver trial. Circulation: Heart Failure, 0(0). https://doi.org/10.1161/CIRCHEARTFAILURE.122.010080
